Ocular Therapeutix(TM) Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI(TM) in Wet AMD

Stock Information for Ocular Therapeutix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ocular Therapeutix Inc.

Ocular Therapeutix(TM) Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI(TM) in Wet AMD
Ocular Therapeutix(TM) Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Ocular Therapeutix(TM) Announces Pricing of Public Offering of Common Stock
Ocular Therapeutix(TM) Announces Proposed Public Offering of Common Stock
Ocular Therapeutix(TM) to Present at Three Upcoming Investor Conferences
Ocular Therapeutix(TM) Provides Third Quarter 2023 Financial Results and Corporate Update
Ocular Therapeutix(TM) Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.